475 related articles for article (PubMed ID: 10449690)
1. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
2. Hyperlipidemia associated with the use of protease inhibitors.
Smith JH; Martin GJ; Decker CF
Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
[No Abstract] [Full Text] [Related]
3. The safety and antiviral effect of protease inhibitors in children.
Temple ME; Koranyi KI; Nahata MC
Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
[TBL] [Abstract][Full Text] [Related]
4. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
5. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
[TBL] [Abstract][Full Text] [Related]
6. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Chang ES; Tetreault DD; Liu YT; Beall GN
J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
[No Abstract] [Full Text] [Related]
7. Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Lai S; Lai H; Celentano DD; Vlahov D; Ren S; Margolick J; Lima JA; Bartlett JG
AIDS Patient Care STDS; 2003 May; 17(5):211-9. PubMed ID: 12816615
[TBL] [Abstract][Full Text] [Related]
8. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
[No Abstract] [Full Text] [Related]
9. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
Hoffmann F; Notheis G; Wintergerst U; Eberle J; Gürtler L; Belohradsky BH
Pediatr Infect Dis J; 2000 Jan; 19(1):47-51. PubMed ID: 10643850
[TBL] [Abstract][Full Text] [Related]
10. Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.
Katner HP; Paar DP; Nadler JP; Jensen EH; Wilson HM; Finn TS; Petruschke RA; Zeldin RK
J Acquir Immune Defic Syndr; 2002 Dec; 31(5):483-7. PubMed ID: 12473836
[TBL] [Abstract][Full Text] [Related]
11. Combinations of protease inhibitors.
TreatmentUpdate; 1998 Apr; 10(2):1-3. PubMed ID: 11365433
[TBL] [Abstract][Full Text] [Related]
12. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR; Cinti SK; Carver PL; Kazanjian PH
Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
[TBL] [Abstract][Full Text] [Related]
13. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.
Young B; Fischl MA; Wilson HM; Finn TS; Jensen EH; DiNubile MJ; Zeldin RK
J Acquir Immune Defic Syndr; 2002 Dec; 31(5):478-82. PubMed ID: 12473835
[TBL] [Abstract][Full Text] [Related]
14. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.
Bonfanti P; Valsecchi L; Parazzini F; Carradori S; Pusterla L; Fortuna P; Timillero L; Alessi F; Ghiselli G; Gabbuti A; Di Cintio E; Martinelli C; Faggion I; Landonio S; Quirino T
J Acquir Immune Defic Syndr; 2000 Mar; 23(3):236-45. PubMed ID: 10839659
[TBL] [Abstract][Full Text] [Related]
15. Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir.
Vandercam B; Moreau M; Horsmans C; Gala JL
Infection; 1998; 26(5):313. PubMed ID: 9795794
[No Abstract] [Full Text] [Related]
16. Effect of protease inhibitors on the sense of taste.
Schiffman SS; Zervakis J; Heffron S; Heald AE
Nutrition; 1999 Oct; 15(10):767-72. PubMed ID: 10501290
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Baldini F; Di Giambenedetto S; Cingolani A; Murri R; Ammassari A; De Luca A
AIDS; 2000 Jul; 14(11):1660-2. PubMed ID: 10983656
[No Abstract] [Full Text] [Related]
18. A patient's guide to protease inhibitors.
Elperin A; Sax P
AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
[TBL] [Abstract][Full Text] [Related]
19. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Anastos K; Lu D; Shi Q; Tien PC; Kaplan RC; Hessol NA; Cole S; Vigen C; Cohen M; Young M; Justman J
J Acquir Immune Defic Syndr; 2007 May; 45(1):34-42. PubMed ID: 17460470
[TBL] [Abstract][Full Text] [Related]
20. Ritonavir and indinavir one year later.
TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
